Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy RAPT Therapeutics stock | $22.96

Own RAPT Therapeutics stock in just a few minutes.


Fact checked

RAPT Therapeutics, Inc is a biotechnology business based in the US. RAPT Therapeutics shares (RAPT) are listed on the NASDAQ and all prices are listed in US Dollars. RAPT Therapeutics employs 71 staff and has a trailing 12-month revenue of around USD$3.7 million.

How to buy shares in RAPT Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for RAPT Therapeutics. Find the stock by name or ticker symbol: RAPT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until RAPT Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$22.96, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of RAPT Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of RAPT Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

RAPT Therapeutics share price

Use our graph to track the performance of RAPT stocks over time.

RAPT Therapeutics shares at a glance

Information last updated 2020-11-30.
Latest market closeUSD$22.96
52-week rangeUSD$10.52 - USD$51.2095
50-day moving average USD$29.0644
200-day moving average USD$27.0624
Wall St. target priceUSD$36.17
PE ratio 0.6299
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.8899

Buy RAPT Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy RAPT Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

RAPT Therapeutics price performance over time

Historical closes compared with the close of $22.96 from 2020-12-09

1 week (2021-01-09) N/A
1 month (2020-12-16) N/A
3 months (2020-10-20) -33.93%
6 months (2020-07-16) N/A
1 year (2020-01-16) N/A
2 years (2019-01-16) N/A
3 years (2018-01-16) N/A
5 years (2016-01-16) N/A

Is RAPT Therapeutics under- or over-valued?

Valuing RAPT Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of RAPT Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

RAPT Therapeutics's P/E ratio

RAPT Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, RAPT Therapeutics shares trade at around 1x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

RAPT Therapeutics financials

Revenue TTM USD$3.7 million
Gross profit TTM USD$0
Return on assets TTM -35.33%
Return on equity TTM -66.41%
Profit margin 0%
Book value $4.493
Market capitalisation USD$550 million

TTM: trailing 12 months

Shorting RAPT Therapeutics shares

There are currently 345,351 RAPT Therapeutics shares held short by investors – that's known as RAPT Therapeutics's "short interest". This figure is 26.8% down from 471,796 last month.

There are a few different ways that this level of interest in shorting RAPT Therapeutics shares can be evaluated.

RAPT Therapeutics's "short interest ratio" (SIR)

RAPT Therapeutics's "short interest ratio" (SIR) is the quantity of RAPT Therapeutics shares currently shorted divided by the average quantity of RAPT Therapeutics shares traded daily (recently around 170965.84158416). RAPT Therapeutics's SIR currently stands at 2.02. In other words for every 100,000 RAPT Therapeutics shares traded daily on the market, roughly 2020 shares are currently held short.

However RAPT Therapeutics's short interest can also be evaluated against the total number of RAPT Therapeutics shares, or, against the total number of tradable RAPT Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case RAPT Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 RAPT Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0311% of the tradable shares (for every 100,000 tradable RAPT Therapeutics shares, roughly 31 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against RAPT Therapeutics.

Find out more about how you can short RAPT Therapeutics stock.

RAPT Therapeutics share dividends

We're not expecting RAPT Therapeutics to pay a dividend over the next 12 months.

RAPT Therapeutics overview

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 2 portion of a Phase 1/2 clinical trial to evaluate as a monotherapy and in combination with pembrolizumab in patients with various types of charged tumors. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into allergically-inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site